Analysis of High Insider Ownership Growth Companies in the U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 01 2026
0mins
Source: Yahoo Finance
- High Insider Ownership: Super Micro Computer boasts 13.9% insider ownership while achieving 50.7% earnings growth, indicating strong performance and future growth potential in the tech sector.
- Profitability Improvement: Abeona Therapeutics recently became profitable with 10.3% insider ownership and is forecasted to grow revenue by 42.5% annually, enhancing its competitive position in gene and cell therapy.
- Market Expansion Potential: Streamex Corp. has 16.1% insider ownership and, despite a financial loss of $15.58 million, is projected to grow revenue by over 100% annually, showcasing its innovative capabilities in asset tokenization.
- Earnings Growth Expectations: Fiverr International, with 11.6% insider ownership, reported a net income of $5.54 million in Q3 2025, with projected earnings growth of 47.5% per year, reflecting strong momentum in the global online marketplace.
Analyst Views on ABEO
Wall Street analysts forecast ABEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABEO is 22.17 USD with a low forecast of 19.00 USD and a high forecast of 27.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.450
Low
19.00
Averages
22.17
High
27.50
Current: 5.450
Low
19.00
Averages
22.17
High
27.50
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
